Pamela Pizzutilo

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 146 citations · Full text

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 95 citations · Full text

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 87 citations · Full text

Advanced Nsclc, Oncology, First-line Pembrolizumab Effectiveness +6

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 82 citations · Full text

Pd-l1 Expression, Clinical Epidemiology, Immunology +8

EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy

Arsela Prelaj, Sara Elena Rebuzzi, Pamela Pizzutilo et al. · Clinical Lung Cancer · 2020 · 80 citations

Prognostic Evaluation, Prognostic Biomarkers, Oncology +8